Open AccessHydrochlorothiazide in CLDN16 mutation
Author(s) -
Bettina Zimmermann,
Christian Plank,
Martin Konrad,
Wolfgang Stöhr,
Chara Gravou-Apostolatou,
Wolfgang Rascher,
Jörg Dötsch
Publication year - 2006
Publication title -
nephrology dialysis transplantation
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.654
H-Index - 168
eISSN - 1460-2385
pISSN - 0931-0509
DOI - 10.1093/ndt/gfl144
Subject(s) - medicine , hypercalciuria , hydrochlorothiazide , nephrocalcinosis , urology , thiazide , endocrinology , diuretic , kidney , calcium , blood pressure
Hydrochlorothiazide (HCT) is applied in the therapy of familial hypomagnesaemia with hypercalciuria and nephrocalcinosis (FHHNC) caused by claudin-16 (CLDN16) mutation. However, the short-term efficacy of HCT to reduce hypercalciuria in FHHNC has not yet been demonstrated in a clinical trial.
Accelerating Research
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom
Address
John Eccles HouseRobert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom